Orris
attachment
attachment

I am posted in hematology under dr sanket shah kindly review refer for hematological cause of thrombosis in this patient

Reading File
analyse_media
Finding Sources
Finding Sources
Searching PubMed

"venous thrombosis"[MeSH Terms] AND thrombophilia

Searching the Web

ASH 2023 thrombophilia testing guidelines venous thromboembolism anticoagulation timing protein C S antithrombin

Hematology opinion: thrombosis workup
From the photograph, the patient appears to be a 49-year-old man with lower-limb DVT for about 7 months, described as having multiple blocks on CT angiography and already on treatment. The displayed screen does not show CBC, coagulation profile, site/extent of thrombosis, provoking factors, anticoagulant, or family history, so a definite hematological cause cannot be assigned from this image alone.

Priority questions

Please establish:
  • Exact thrombotic sites: proximal/distal DVT, iliac/IVC involvement, arterial occlusion, cerebral/splanchnic thrombosis.
  • Whether this was unprovoked, recurrent, progressive despite adequate anticoagulation, or occurred at an unusual site.
  • Recent surgery/trauma/immobilisation, infection, smoking, obesity, malignancy symptoms, testosterone/anabolic agents, nephrotic syndrome, autoimmune symptoms.
  • Personal/family history of VTE at young age.
  • Current anticoagulant and duration, plus adherence and renal/hepatic function.

Hematological evaluation

1. Basic evaluation now
  • CBC with platelet count and peripheral smear
  • PT/INR, aPTT, fibrinogen
  • LFT, RFT, urine protein/albumin
  • LDH, bilirubin, reticulocyte count, haptoglobin if anemia, cytopenia, high LDH, or hemolysis suspected
  • ESR/CRP as clinically indicated
2. Antiphospholipid syndrome (APS) Appropriate particularly if thrombosis is unprovoked, recurrent, arterial plus venous, extensive, or occurring despite treatment:
  • Lupus anticoagulant
  • Anticardiolipin antibody IgG/IgM
  • Anti-beta-2 glycoprotein I antibody IgG/IgM
A positive APS test must be repeated after at least 12 weeks for confirmation. Lupus anticoagulant interpretation is unreliable on heparin, warfarin, and especially DOAC therapy, so coordinate timing and laboratory method with hematology. APS is an important acquired cause of both venous and arterial thrombosis; the standard laboratory antibodies are LA, anticardiolipin, and anti-beta-2-glycoprotein I. ASH thrombophilia guidance
3. Myeloproliferative neoplasm (MPN) screen Because of “multiple blocks,” assess CBC trend carefully:
  • Persistent thrombocytosis, erythrocytosis, leukocytosis, splenomegaly, aquagenic pruritus, or unusual-site thrombosis should prompt:
    • JAK2 V617F
    • If JAK2 negative with erythrocytosis/thrombocytosis: hematology-directed CALR/MPL testing and further MPN workup.
4. PNH testing Do flow cytometry for CD55/CD59 or FLAER-based PNH assay only if there is:
  • Unusual-site thrombosis, especially hepatic/splanchnic/cerebral venous thrombosis
  • Cytopenias
  • Hemolysis or high LDH
  • Dark urine or marrow-failure features
5. Inherited thrombophilia If event is unprovoked/recurrent, at a young age, with strong family history, or at an unusual site, consider:
  • Factor V Leiden
  • Prothrombin G20210A mutation
  • Antithrombin deficiency
  • Protein C deficiency
  • Protein S deficiency
However, do not interpret protein C, protein S, or antithrombin levels during acute thrombosis or while on interfering anticoagulants. Warfarin lowers protein C/S; heparin and DOACs can affect some functional assays. Genetic tests for Factor V Leiden/prothrombin mutation are not affected by anticoagulation.

Important management point

Do not stop anticoagulation simply to send thrombophilia tests. The immediate priority is confirming adequate therapeutic anticoagulation, assessing clot extent/progression, and excluding an active provoking condition. Testing should only be ordered if the result will change duration/type of anticoagulation or family counselling. ASH recommends selective rather than routine thrombophilia testing, particularly considering it for young patients, recurrent VTE, unusual-site thrombosis, or relevant family history. ASH 2023 guideline

Suggested note for Dr Sanket Shah

Hematology review requested for possible prothrombotic state in 49-year-old male with chronic/extensive lower-limb DVT and reported multiple vascular blocks. Please provide venous Doppler/CT angiography report, CBC trends, coagulation profile, current anticoagulant with dose/adherence, prior thrombotic episodes, provoking factors, family history, and evidence of arterial/unusual-site thrombosis.
Recommend CBC with smear, PT/INR, aPTT, fibrinogen, LFT/RFT, urine protein, and targeted APS testing. Evaluate for MPN with JAK2 V617F if CBC abnormal or thrombosis is extensive/unusual. Consider PNH flow cytometry only if cytopenias, hemolysis, or unusual-site thrombosis. Inherited thrombophilia testing should be selective and timed to avoid anticoagulant/acute-phase assay interference.
Recent systematic reviews continue to support increased VTE risk with hereditary thrombophilia, but results must be interpreted in the clinical context and do not automatically determine indefinite anticoagulation: 2024 meta-analysis and 2026 recurrence review.

Create a concise hematology referral note for Dr. Sanket Shah

Reading File
Finding Sources
Searching PubMed

"venous thrombosis"[MeSH Terms] AND thrombophilia

Searching the Web

ASH thrombophilia testing guideline venous thrombosis 2023

To: Dr. Sanket Shah, General Medicine
Re: Hematology opinion for thrombosis evaluation
Patient: Mr. Bhavin Sureshchandra Shukla, 49-year-old male
Clinical issue: Lower-limb DVT for approximately 7 months, with reported multiple vascular blocks on imaging.
Kindly evaluate for an underlying prothrombotic disorder, particularly given the chronic/extensive nature of thrombosis.
Suggested workup
  • CBC with platelet count and peripheral smear
  • PT/INR, aPTT, fibrinogen
  • LFT, RFT, urine protein/albumin
  • Antiphospholipid antibody profile: lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta-2 glycoprotein I IgG/IgM
  • JAK2 V617F mutation if thrombocytosis, erythrocytosis, leukocytosis, splenomegaly, or unusual-site thrombosis
  • PNH flow cytometry if cytopenias, hemolysis/high LDH, or unusual-site thrombosis
  • Consider selective inherited thrombophilia testing: Factor V Leiden, prothrombin G20210A, antithrombin, protein C and protein S deficiency, based on provoking factors, family history, recurrence, and site of thrombosis.
Please correlate with Doppler/CT angiography findings, anticoagulant type/dose/adherence, CBC trend, prior thrombotic events, family history, malignancy screen, and provoking factors.
Note: Protein C, protein S, antithrombin, and lupus anticoagulant assays may be affected by acute thrombosis and ongoing anticoagulation. Anticoagulation should not be interrupted solely for thrombophilia testing.
This is a shared conversation. Sign in to Orris to start your own chat.